Trending: GSK Signs $3 Billion Shingles Vaccine Deal in China
1008 GMT - GSK has been among the most mentioned companies across news items over the past four hours, according to Factiva data. Shares of the British pharmaceutical giant rose 0.9% after it said it agreed on a deal valued at 2.5 billion pounds ($3.06 billion) with Chongqing Zhifei Biological Products for the exclusive distribution of its shingles vaccine in China. The three-year deal will start from Jan. 1 and has the option to be further extended. Dow Jones & Co. owns Factiva. (michael.susin@wsj.com)
(END) Dow Jones Newswires
October 09, 2023 06:23 ET (10:23 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks